JP2009517401A5 - - Google Patents

Download PDF

Info

Publication number
JP2009517401A5
JP2009517401A5 JP2008542528A JP2008542528A JP2009517401A5 JP 2009517401 A5 JP2009517401 A5 JP 2009517401A5 JP 2008542528 A JP2008542528 A JP 2008542528A JP 2008542528 A JP2008542528 A JP 2008542528A JP 2009517401 A5 JP2009517401 A5 JP 2009517401A5
Authority
JP
Japan
Prior art keywords
butyl
methyl
chloro
aldehyde
bromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008542528A
Other languages
English (en)
Japanese (ja)
Other versions
JP5460054B2 (ja
JP2009517401A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/061219 external-priority patent/WO2007062399A2/en
Publication of JP2009517401A publication Critical patent/JP2009517401A/ja
Publication of JP2009517401A5 publication Critical patent/JP2009517401A5/ja
Application granted granted Critical
Publication of JP5460054B2 publication Critical patent/JP5460054B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008542528A 2005-11-23 2006-11-22 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法 Expired - Fee Related JP5460054B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73986505P 2005-11-23 2005-11-23
US60/739,865 2005-11-23
PCT/US2006/061219 WO2007062399A2 (en) 2005-11-23 2006-11-22 Oncogenic ras-specific cytotoxic compound and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2009517401A JP2009517401A (ja) 2009-04-30
JP2009517401A5 true JP2009517401A5 (https=) 2010-07-29
JP5460054B2 JP5460054B2 (ja) 2014-04-02

Family

ID=38068056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008542528A Expired - Fee Related JP5460054B2 (ja) 2005-11-23 2006-11-22 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法

Country Status (8)

Country Link
US (1) US8883841B2 (https=)
EP (1) EP1956910B1 (https=)
JP (1) JP5460054B2 (https=)
CN (1) CN101360422B (https=)
AU (1) AU2006318212C1 (https=)
CA (1) CA2631082C (https=)
RU (1) RU2448703C2 (https=)
WO (1) WO2007062399A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL212489B1 (pl) 2008-01-22 2012-10-31 Univ Jagiellonski Pochodne fenoksyalkiloaminoalkanoli i ich zastosowania
CA2720275A1 (en) * 2008-04-01 2009-10-08 Astellas Pharma Inc. Indolinone compound
CN102137658A (zh) * 2008-06-30 2011-07-27 斯兰斯德有限公司 局部递送药物的方法、组合物和系统
US8304421B2 (en) 2008-09-30 2012-11-06 Vanderbilt University Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
EP2385829B1 (en) 2009-01-09 2018-08-01 Board of Regents of the University of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9095572B2 (en) 2009-01-09 2015-08-04 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
WO2011060976A1 (en) * 2009-11-20 2011-05-26 Universite De Liege Tryptamine-derived compounds as antibacterial agents
CA2784024C (en) * 2009-12-16 2018-03-13 Yvon Durant Emulsion polymerization of esters of itaconic acid
US9526709B2 (en) 2011-04-06 2016-12-27 Chemo-Enhanced Llc Compositions and methods for treating cancer
US9474730B2 (en) * 2012-04-30 2016-10-25 Board Of Regents Of The University Of Texas System Methods and compositions for use with K-ras mediated disorders
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN104903308B (zh) 2013-01-10 2018-06-08 默克专利股份有限公司 作为抗疟药的哌啶基咔唑类
CA2936345A1 (en) 2013-01-14 2014-07-17 Chemo-Enhanced Llc Compositions and methods for treating cancer
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
WO2015070234A2 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
MA40074A (fr) * 2014-05-30 2015-12-03 Univ Columbia Composés liant ras multivalents
WO2015192343A1 (en) * 2014-06-18 2015-12-23 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences P53 activator small molecules
CN111533734A (zh) 2014-07-04 2020-08-14 默克专利股份有限公司 具有抗寄生虫活性的氮杂环庚烷基衍生物和包含它们的药物组合物
US10736877B2 (en) 2015-12-31 2020-08-11 Syracuse University Tryptamine-based ship inhibitors for the treatment of cancer
CN108602775B (zh) 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
US10918650B2 (en) * 2016-06-02 2021-02-16 University Of South Florida Method of treating melanoma using an inhibitor of an atypical protein kinase C
WO2018058029A1 (en) 2016-09-26 2018-03-29 Dana-Farber Cancer Institute, Inc. Chromobox protein inhibitors and uses thereof
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
BR112019012263A2 (pt) 2016-12-15 2020-01-28 The Regents Of The University Of California composições e métodos para tratar câncer
CN108251377B (zh) * 2018-01-16 2021-08-27 内蒙古大学 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法
US10738139B2 (en) 2018-12-18 2020-08-11 Itaconix Corporation Decarboxylation and amidation of polyitaconic acid polymers
KR102620902B1 (ko) * 2020-04-24 2024-01-04 가천대학교 산학협력단 신규 알파-시누클레인 방사성 리간드 및 이를 포함하는 신경퇴행성 질환 진단용 조성물
KR102428024B1 (ko) * 2020-06-11 2022-08-03 충북대학교 산학협력단 프로카스파제-3의 활성화제로서 신규한 (e)-n-아릴리덴-1-(4-클로로벤질)-1h-인돌-3-카보하이드라지드 및 이를 유효성분으로 포함하는 항암제 조성물
KR102617885B1 (ko) * 2021-05-07 2023-12-27 충북대학교 산학협력단 신규한 (e)-n'-((1-(4-클로로벤질)-1h-인돌-3-일)메틸렌)-2-(4-옥소퀴나졸린-3(4h)-일)아세토히드라지드 화합물 및 이를 유효성분으로 포함하는 항암제 조성물

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
DK0746544T3 (da) 1994-02-22 1999-06-07 Merrell Pharma Inc Indolderivater til behandling af østrogenafhængige neoplasmer og sygdomme
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6027726A (en) 1994-09-30 2000-02-22 Inex Phamaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
ATE285477T1 (de) 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
US20010007877A1 (en) * 1998-12-16 2001-07-12 George O. Burton Novel anti-infectives
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
DE60023920T2 (de) * 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphatmimetika und Verfahren zur Behandlung mit Phosphataseinhibitoren HIBITOREN
US6900043B1 (en) * 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
WO2001077114A1 (en) * 2000-04-10 2001-10-18 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
PL366068A1 (en) 2000-10-10 2005-01-24 Smithkline Beecham Corporation Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents
WO2003022274A2 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer
EP1484329A1 (de) 2003-06-06 2004-12-08 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
BRPI0410998A (pt) 2003-06-05 2006-07-04 Zentaris Gmbh derivados de indol com efeito de indução de apoptose
US7371875B2 (en) * 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use

Similar Documents

Publication Publication Date Title
JP2009517401A5 (https=)
RU2008125065A (ru) ОНКОГЕННОЕ Ras-СПЕЦИФИЧЕСКОЕ ЦИТОТОКСИЧЕСКОЕ СОЕДИНЕНИЕ И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
JP2011511806A5 (https=)
US20220153738A1 (en) Compositions and methods for modulating hair growth
US9518044B2 (en) Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
AP869A (en) 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
JP2019521988A (ja) 癌を処置するためのｅｚｈ２阻害剤
WO2020142413A1 (en) Compositions and methods for modulating hair growth
FI3307727T3 (fi) Erk1:n ja erk2:n heterosyklisiä estäjiä ja niiden käyttö syövän hoidossa
US8946282B2 (en) Indolin-2-one derivatives as protein kinase inhibitors
WO2014194848A1 (zh) 多靶点型乌苯美司前药衍生物及其制备方法和用途
CN102089303A (zh) 含氮杂环化合物
CN102149412A (zh) 肝脏保护剂对乙酰氨基酚协同前药
AU2008233553A1 (en) Indole derivative having cPLA2 inhibitory activity, use of the same and method for producing the same
NZ596820A (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
WO2022216379A1 (en) Combination therapies for the treatment of cancer
AU2023241042A1 (en) Compositions and methods for treating cancer
TW200914022A (en) Synergistic combinations
CN114829330A (zh) 雄激素受体n端结构域的抑制剂
AU2012332111B2 (en) Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
AU2016226036B2 (en) Salicylate inhibitors of MELK and methods of use
US11077097B2 (en) Use of aromatic ring drug in inhibiting key transcription factor of malignant melanoma
JP2008179567A (ja) ピラジン誘導体を有効成分とする抗がん剤
CA2686787A1 (en) Raf inhibitors for the treatment of thyroid cancer
JP2010500971A5 (https=)